You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Self-Supervised Training in Geospatial Applications with a Robust Hierarchical Vision Transformer (STAR)SBC: UNIVERSITY TECHNICAL SERVICES, INC. Topic: OSD22A001
Satellite Imagery in Geospatial Intelligence (GEOINT), in conjunction with imagery intelligence (IMINT), geospatial information, and other means of gaining intelligence, has greatly improved the potential of the warfighter and decision makers enabling them to gain a more comprehensive perspective, an in-depth understanding, and a cross-functional awareness of the operational environment. The Artif ...STTR Phase I 2022 Department of DefenseNational Geospatial-Intelligence Agency
SBC: Renova Therapeutics, Inc. Topic: NHLBI
ABSTRACT Type-1 Diabetes Mellitus (T1DM) affects 1.25 million patients in US with 40,000 new patients annually. Lifespan is shortened 11-13 years, due to kidney and heart disease. Tight glucose control reduces microvascular complications and adverse cardiovascular events. Insulin therapy is essential for such patients, but has shortcomings: a) only 1 in 3 patients achieve targeted glucose control ...STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
Preclinical testing of a 3D printed external scaffold device to prevent vein graft failure after coronary bypass graft surgerySBC: BIOGRAFT, INC. Topic: NHLBI
Saphenous vein graft (SVG) failure following coronary artery bypass grafting (CABG) is a critical clinical problem, with recent studies revealing that as many as 25% of vein grafts develop stenosis within 12-18 months after surgery, and up to 50% of grafts occlude within 5-10 years. CABG surgery is the gold standard treatment for patients with severe multi-vessel disease, with over 370,000 procedu ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
Assessment of mobile application-delivered lighting interventions for reducing circadian disruption in shift workersSBC: ARCASCOPE INC. Topic: NHLBI
PROJECT SUMMARY Shift workers experience profound circadian disruption, which can have deleterious long term effects on their health and quality of life. Mood, fatigue, and performance can be improved in shift workers by moving the timing of their peak circadian drive to sleep outside the hours they are expected to work. This can be achieved with a targeted lighting intervention, as light is the p ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: L2 DIAGNOSTICS LLC Topic: NIAID
SUMMARY Arboviruses present a constant threat to human and animal health worldwide. They are transmitted by hematophagous arthropods, primarily mosquitoes. One of them, Aedes aegypti, is the primary vector of several widely spread arboviruses such as Zika, dengue and West Nile viruses, and for most of them, human-licensed vaccines do not exist or are suboptimal. These pathogens are transmitted int ...STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: MelioLabs Inc. Topic: NICHD
PROJECT SUMMARY Since 2014, Congenital Syphilis (CS) cases in the United States, caused by the transplacental transmission of the bacterium Treponema pallidum from mother to child, have increased at an alarming rate. Targeted surveillance studies indicate a rise andgt;185% from 2014 to 2018 alone. Women who acquire syphilis within 4 years of pregnancy will transmit the infection to 80% of their fe ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: Cohere-Med, Inc. Topic: 300
Abstract This fast-track STTR application proposes to enhance, validate, and scale Sepsis Watch, a deep learning sepsis detection and management system built using data from the Emergency Department (ED) Duke University Hospital (DUH). The proposal will extend and enhance Sepsis Watch to EDs, general inpatient wards, and intensive care unit (ICU) settings across multiple health systems in the Unit ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: INFRATRAC INC Topic: NIAID
Precise, customizable drug delivery remains a long-term goal, for HIV in particular, as such technologies would allow therapies tailored to a patient’s biological makeup and potentially improve adherence. Extended-release methods address part of the issue, but face limitations. A novel drug delivery system could offer better pediatric dosing, via both oral and new routes of administration. Exist ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
Developing Vertebrate-Specific Replication-Defective Dengue Virus as Novel Single-CycleDengue Vaccine CandidateSBC: Tengen Biomedical Co Topic: NIAID
Developing Vertebrate-Specific Replication-Defective Dengue Virus asa Novel Single-Cycle Dengue Vaccine Candidate Abstract With an estimated minimum of 390 million dengue virus (DENV) infections per year, the DENV epidemic was listed as one of the world's top 10 public health threats by WHO in 2019. At present, there is no specific treatment. A universal vaccine is urgently needed. DENV vaccine de ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: Vesicle Therapeutics Inc. Topic: NHLBI
Project Summary Vesicle Therapeutics Inc aims to develop and commercialize a new therapy for homozygous familial hypercholesterolemia (hoFH). A majority of hoFH is caused by mutations in both alleles of the gene encoding the LDL receptor (LDLR). Since the efficacy of both statins and PCSK9 antibody therapies largely depends on functional LDL receptors, patients with hoFH show limited responses to ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health